Serina Therapeutics Announces Filing of Investigational New Drug (IND) Application for SER-214 for the Treatment of Parkinson’s Disease Read More
Serina Therapeutics Announces Follow-on Agreement with AstraZeneca for Development of a Proprietary POZ-therapeutic Read More
Serina Therapeutics Announces Close of $ 5 Million Financing to Advance SER-214 and Polymer Oncology Programs Read More
Serina Therapeutics to Co-Sponsor Session on Poly(2-oxazoline)s and Polypeptoids at American Chemical Society in San Francisco August 10-12th 2014 Read More
Serina Therapeutics’ CEO Selected as Panelist at 2014 Neurotech Investing and Partnering Conference Read More
Serina Therapeutics’ CEO Will Lead Session on Biorelated Polymers at the 12th International Symposium of the American Chemical Society Read More
Serina Therapeutics Announces Issuance of Key Patents in China and Europe Extending the POZ Patent Estate Globally Read More
Serina Therapeutics Announces Publication of SER-214 (POZ-Rotigotine) Article in Journal of Movement Disorders Read More
Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates Read More
Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank Read More